ClinicalTrials.gg
Active, not recruitingNCT05918380Updated Aug 28, 2026

Project 3: ACHIEVE- CHD

An interventional study of PAL2 and CINEMA in Coronary Heart Disease, sponsored by University Hospitals Cleveland Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by University Hospitals Cleveland Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Aug 2022, registered Jun 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.

Planned enrollment
57th of 184
500 · median 200
Started
2022
with 1 other
No phase
78 of 274
6 open now
Primary completion
2027-01
later than 7 of 22 live
Registered
259th of 274
by date

Among the 274 studies in Coronary Disease with a site in United States, this one is the 57th largest by planned enrollment of the 184 interventional ones that give a count, is one of 2 that started in 2022, is one of 78 with no phase, reaches primary completion later than 7 of the 22 other live ones, and was the 259th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 274 studies in Coronary Disease with a site in United States, or all of them as a file.
02

Study summary

This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities and downstream Black-White lifespan inequality in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center will involve three separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Project 2) and coronary heart disease (CHD, Project 3), which drive downstream lifespan inequality. All three projects will involve the use of Community Health Workers (CHWs) to deliver an evidence-based practice intervention program called PAL2. All three projects will also utilize the PAL2 Implementation Intervention (PAL2-II), which is a set of structured training and evaluation strategies designed to optimize CHW competence and adherence (i.e., fidelity) to the PAL2 intervention program. The present study is Project 3 of the ACHIEVE GREATER Center.

03

Conditions studied

  • Coronary Heart Disease

Browse trials for

Keywords

  • Health Disparities
  • African American
  • Prevention
  • Coronary Heart Disease
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 40 to 75 years of age
  2. Self-identified as Black or African American
  3. Residence in the Cleveland Metro Area
  4. Must have at least two of the following risk factors identified at a UH health fair screenings, with one risk factor being with SBP, A1c, or LDL:

    1. ≥30 mg/dL
    2. History of smoking
    3. Elevated blood pressure defined as SBP>140 or DBP>80 mmHg
    4. ≥5.7%
    5. LDL≥130
  5. Able to complete a coronary artery calcium score test (CAC)
  6. Willing and able to consent
  7. Willing to have a UH provider and UH care
  8. Currently insured for standard of care procedures

Exclusion criteria

Exclusion Criteria:

  1. Established documented cardiovascular disease (coronary artery disease, peripheral artery disease, myocardial infarction, stroke).
  2. Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg
  3. Lung disease requiring supplemental oxygen therapy
  4. Individuals receiving treatment for cancer related disease
  5. Pregnant or nursing mothers
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Other
    Low CVD risk

    PAL2

    Behavioral: PAL2

  • Other
    High CVD risk

    Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA)

    Other: CINEMA

Interventions

  • BehavioralPAL2

    Low CVD risk participants (CAC \< 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2. PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education.

    Also known as: Pragmatic personalized, adaptable approach to lifestyle and life circumstance

  • OtherCINEMA

    High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.

06

What researchers measure

Primary outcomes

  1. Triple Goal

    Percent reaching triple goal of BP \<130/80 mm Hg, HbA1c\<5.7% and LDL-C \<130 mg/dl (\<100 if high-risk)

    Time frame: 12 months

Secondary outcomes

  1. Change in HbA1c as measured by blood work

    Percent change in HbA1c

    Time frame: baseline, 12 months

  2. Change in LDL-C as measured by blood work

    Percent change in LDL-C

    Time frame: baseline, 12 months

  3. Change in blood pressure

    Percent change in blood pressure

    Time frame: baseline, 12 months

  4. Change in weight

    Percent change in weight

    Time frame: baseline, 12 months

Other outcomes

  1. Health Visits and Lifestyle Changes - Medical/Mental Health Visits

    1-year rate of new medical/mental health visits

    Time frame: 12 months after cessation of intervention or 24 months after enrollment

  2. Health Visits and Lifestyle Changes - Smoking Cessation

    1-year rate of smoking cessation

    Time frame: 12 months after cessation of intervention or 24 months after enrollment

  3. Health Visits and Lifestyle Changes - Diet

    1-year rate of changes in diet

    Time frame: 12 months after cessation of intervention or 24 months after enrollment

  4. Health Visits and Lifestyle Changes - Activity

    1-year rate of changes in activity

    Time frame: 12 months after cessation of intervention or 24 months after enrollment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Jan 2027, 52 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 52 months is above that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 26, 2023
StartActual
Aug 15, 2022
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05918380
Responsible party
Sanjay Rajagopalan (Chief, Cardiovascular Medicine, Chief Academic and Scientific Officer, University Hospitals Cleveland Medical Center) — Principal investigator
First posted
Jun 26, 2023
Start date
Aug 15, 2022
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Aug 28, 2026

Study contacts

Sanjay Rajagopalan, MD
principal investigator · University Hospitals Cleveland Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion